Vigorous development of Chengdu biomedical industry is speeding up to 100 billion

[industry trends of China Pharmaceutical network] if we want to use a word to describe Chengdu's biomedical industry, it is booming In recent years, Chengdu has invested a lot of energy in the biomedical industry, including introducing biomedical projects, attracting talents, encouraging biomedical enterprises to go to Hong Kong for listing, etc All these measures have added new impetus to the development of biomedicine in Chengdu The author understands that 18 key projects have been signed and settled in Chengdu Tianfu international biological city recently, with a total investment of more than 26 billion yuan Among the contracted projects, there are 10 industrial chain projects, 4 innovation chain projects, 3 financial chain projects and 1 supply chain project In terms of varieties, it is expected to produce 12 clinical approval documents for class I new drugs, 2 production approval documents for class I new drugs, 9 clinical approval documents for domestic first generic drugs and 16 production approval documents for domestic first generic drugs Specifically, among the 10 industrial chain projects, including the international R & D and production base of antibody drugs, the global subcutaneous injection of PD-L1 antibody drugs, the production base of immunotherapy drugs based on new targets and the international biological service R & D and production base, etc Among the four innovation chain projects, Professor kohnberg, the Nobel Prize winner, and non living creatures cooperated to build a research and development platform for monoclonal antibody and bispecific nano antibody innovative biomacromolecule drugs, an international standard clinical service center, a global life and health industry resource evaluation and trading center, etc Three financial chain projects include customized services for innovative biological enterprises in terms of insurance and fund In terms of the introduction of biomedical talents, Chengdu has continued to make efforts Chengdu Science and Technology Bureau disclosed in the work of Chengdu Science and technology innovation in 2017 that by the end of 2017, Chengdu had 32 academicians of the "two academies", 672 experts of the "thousand talents plan" of Sichuan Province and 463 experts of the "talent plan" of Chengdu The key projects and the continuous injection of talents are inseparable from the construction of Chengdu biomedical industry infrastructure Taking Chengdu Tianfu international bio city as an example, at present, Chengdu hi tech Zone is taking bio city as the core carrier, building a bio industry functional area in an all-round way, and building an industrial ecosystem of "four chains, one community and one system" to support the innovation and Entrepreneurship of bio pharmaceutical industry Relevant leaders also said that in the future, Tianfu international bio city will concentrate its efforts in the four main directions of biomedicine, biomedical engineering, biological services and health new economy, and devote itself to cultivating the biological industry into a new 100 billion level industry in Chengdu after the electronic information industry The biomedical industry is bringing new vitality to Chengdu In order to develop the biomedical industry better and faster, relevant departments organized and held a training meeting on the listing of biomedical enterprises in Hong Kong and equity financing Xie ruiwu, member of the Standing Committee of the CPC Chengdu Municipal Committee and executive vice mayor, said that he hoped that biomedical enterprises could seize the opportunity to realize leapfrog development, provide better support and make greater contribution to Chengdu's going to the country and the world Mao Zhirong, managing director of the Hong Kong stock exchange, also said that over the past two or three decades, the development of the exchange has been closely linked to the economy of the mainland At the same time, the development of biotechnology industry in the mainland has made rapid progress and made a very big breakthrough Generally speaking, HKEx has advantages in transparency of listing approval system, predictable listing schedule, rich refinancing channels, and opportunities for interconnection At present, the conversion rate of biomedical achievements in China has remained at about 5%, and the development is relatively lagging behind Relevant experts also said that the transformation of China's pharmaceutical innovation needs open and free policies and markets, the support of scientists and talented entrepreneurs, and many challenges in the field of biomedicine waiting for enterprises to overcome In this regard, Chengdu is giving full play to its professionalism, tapping potential economic strength and improving the openness of the biomedical field In order to better develop the biomedical industry, relevant departments are constantly communicating with enterprises and using innovative thinking to strive to build Chengdu into a strong biomedical industry development city.